Cargando…
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification o...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618303/ https://www.ncbi.nlm.nih.gov/pubmed/28792479 http://dx.doi.org/10.3390/biomedicines5030045 |
_version_ | 1783267155876249600 |
---|---|
author | Kruspe, Sven Giangrande, Paloma H. |
author_facet | Kruspe, Sven Giangrande, Paloma H. |
author_sort | Kruspe, Sven |
collection | PubMed |
description | Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification of cell-specific, cell-internalizing aptamers for the cell-targeted delivery of therapeutic oligonucleotides. In addition, we review the original, proof-of-concept aptamer-siRNA delivery studies and discuss recent advances in aptamer-siRNA conjugate designs for applications ranging from cancer therapy to the development of targeted antivirals. Challenges and prospects of aptamer-targeted siRNA drugs for clinical development are further highlighted. |
format | Online Article Text |
id | pubmed-5618303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56183032017-09-29 Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects Kruspe, Sven Giangrande, Paloma H. Biomedicines Review Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification of cell-specific, cell-internalizing aptamers for the cell-targeted delivery of therapeutic oligonucleotides. In addition, we review the original, proof-of-concept aptamer-siRNA delivery studies and discuss recent advances in aptamer-siRNA conjugate designs for applications ranging from cancer therapy to the development of targeted antivirals. Challenges and prospects of aptamer-targeted siRNA drugs for clinical development are further highlighted. MDPI 2017-08-09 /pmc/articles/PMC5618303/ /pubmed/28792479 http://dx.doi.org/10.3390/biomedicines5030045 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kruspe, Sven Giangrande, Paloma H. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title_full | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title_fullStr | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title_full_unstemmed | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title_short | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects |
title_sort | aptamer-sirna chimeras: discovery, progress, and future prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618303/ https://www.ncbi.nlm.nih.gov/pubmed/28792479 http://dx.doi.org/10.3390/biomedicines5030045 |
work_keys_str_mv | AT kruspesven aptamersirnachimerasdiscoveryprogressandfutureprospects AT giangrandepalomah aptamersirnachimerasdiscoveryprogressandfutureprospects |